Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Diabetes Mellitus, Type 2: full-pipeline trial registry
63 of 351 indexed Diabetes Mellitus, Type 2 trials are currently recruiting.
Corpus placement: #18 of 28,707 conditions by registered trial count.
351 US clinical trials · 63 currently recruiting · #18 of 28,707 conditions by registered trial count
Diabetes Mellitus, Type 2: 351 US clinical trials tracked, 63 recruiting.
Diabetes Mellitus, Type 2 is the subject of 351 registered US clinical trials on ClinicalTrials.gov, 63 of them currently open to new participants. 100 are in Phase 3-4 (later-stage) and 80 in Phase 1-2 (earlier-stage). The most active sponsor is Novo Nordisk A/S, running 48 of these trials.
Enrollment posture brief
Registry condition diabetes-mellitus-type-2
OPEN 63 | RECR 18% | LATE 100 | EARLY 80 | RANK #18 | SPON 48
Volume-matched condition peers
Nearest open-share peer: Acute Myelogenous Leukemia (18% recruiting · 39 trials)
Diabetes Mellitus, Type 2 lists 63 open slots (18% of 351 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Diabetes Mellitus, Type 2 on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Diabetes Mellitus, Type 2 is recruiting below its size-band peers.
63 of 351 indexed trials (17.9%) are open to enrollment, against a 37.1% average across 139 conditions with 100+ trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
Sponsorship of Diabetes Mellitus, Type 2 trials is spread across many organizations.
Novo Nordisk A/S accounts for 48 of 351 trials (13.7%). 143 distinct sponsors appear on at least one study for this condition label.
-
Typical Diabetes Mellitus, Type 2 enrolment sits around 150 participants.
Median target enrolment is 150 among the 349 trials that report a genuine target (sentinel values excluded). 142 of those (40.7%) plan for fewer than 100 participants.
-
Diabetes Mellitus, Type 2 research is mostly interventional.
321 interventional and 30 observational studies make up this index (91.5% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
351 total, page 4 of 8
Diabetes Coaching Program for Medicare Advantage Members With Type 2 Diabetes - Impact on A1c
Evidation Health
NCT03363100
Impact of Dietary Intervention on Weight Change in Subjects With Type 2 Diabetes
Novo Nordisk A/S
NCT01232491
Project MiNT: Assessing the Impact of Food & Video-Based Nutrition Education on Patients With Poorly Controlled Diabetes
Thomas Jefferson University
NCT04264572
Vildagliptin Compared to Pioglitazone in Combination With Metformin in Patients With Type 2 Diabetes
Novartis
NCT00237237
A Research Study to Compare Two Types of Insulin, a New Insulin, Insulin Icodec and an Available Insulin, Insulin Degludec, in People With Type 2 Diabetes Who Have Not Used Insulin Before (ONWARDS 3)
Novo Nordisk A/S
NCT04795531
Gan & Lee Insulin Glargine Target Type (2) Evaluating Research
Gan and Lee Pharmaceuticals, U
NCT03371108
Comparative Effectiveness of Family DSMES and Standard DSMES Among Diverse Populations
University of Arkansas
NCT04334109
Efficacy and Safety of Vildagliptin in Combination With Metformin in Patients With Type 2 Diabetes
Novartis Pharmaceuticals
NCT00099892
Understanding and Improving Diabetes Care for Ethnic Minorities
University of California, Irvine
NCT01123239
Evaluation of Insulin Glargine Versus Sitagliptin in Insulin-naive Patients
Sanofi
NCT00751114
NovoLog Observation Trial in Subjects With Type 1 and Type 2 Diabetes
Novo Nordisk A/S
NCT00095446
A Research Study to See How Semaglutide Helps People With Excess Weight and Type 2 Diabetes Lose Weight
Novo Nordisk A/S
NCT05649137
A Safety and Efficacy Study Comparing Naltrexone SR/Bupropion SR and Placebo in Obese Subjects With Type 2 Diabetes
Orexigen Therapeutics
NCT00474630
Comparison of Insulin Detemir Morning, Insulin Detemir Evening and NPH Insulin Evening in Patients With Type 2 Diabetes
Novo Nordisk A/S
NCT00104182
A Study of LY2963016 Compared to LANTUS® in Adult Participants With Type 2 Diabetes Mellitus
Eli Lilly and Company
NCT02302716
GLP-1 Receptor Agonist Lixisenatide in Patients With Type 2 Diabetes for Glycemic Control and Safety Evaluation, on Top of Metformin
Sanofi
NCT00763451
Comparison of Two Basal Insulins for Patients With Type 2 Diabetes on Anti-Hyperglycemic Medications (IOPE)
Eli Lilly and Company
NCT00510952
Comparison of NN1250 With Insulin Glargine in Subjects With Type 2 Diabetes
Novo Nordisk A/S
NCT01076647
Comparison of NN5401 With Insulin Glargine, Both in Combination With Oral Antidiabetic Drugs, in Subjects With Type 2 Diabetes
Novo Nordisk A/S
NCT01045447
Comparison of NN1250 With Sitagliptin in Subjects With Type 2 Diabetes Never Treated With Insulin
Novo Nordisk A/S
NCT01046110
The Efficacy of Insulin Degludec/Liraglutide as add-on Therapy in Controlling Glycaemia in Adults With Type 2 Diabetes Inadequately Controlled on Sulphonylurea With or Without Metformin Therapy
Novo Nordisk A/S
NCT01618162
Comparison of TAK-875 (Fasiglifam) With Placebo in Participants With Type 2 Diabetes
Takeda
NCT01456195
A Study to Compare a New Drug for Type 2 Diabetes to Placebo and to a Treatment Already Available for Type 2 Diabetes
OPKO Health
NCT02119819
Home Food Delivery for Diabetes Management in Patients of Rural Clinics
University of Arkansas
NCT04876053
A Study to Evaluate the Effect of ASP1941 in Adult Patients With Type 2 Diabetes Mellitus
Astellas Pharma
NCT01071850
Evaluation of Glucose Lowering Effect, Safety and Tolerability of CS-917
Daiichi Sankyo
NCT00290940
Diabetes Prevention Program Lifestyle Intervention in the Marshallese Population
University of Arkansas
NCT03270436
Compare Two Dosing Algorithms in Insulin-Naive Patients With Type 2 Diabetes Mellitus
Eli Lilly and Company
NCT00391209
Comparison of Two Insulin Degludec Formulations in Subjects With Type 2 Diabetes Mellitus
Novo Nordisk A/S
NCT01364428
A Study of Taspoglutide Versus Placebo for the Treatment of Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Diet and Exercise.
Hoffmann-La Roche
NCT00744926
Mitiglinide in Combination With Metformin vs. Metformin Alone in Patients With Type 2 Diabetes Mellitus
Elixir Pharmaceuticals
NCT00519142
English Diabetes Self-Management Program
Stanford University
NCT00684086
The Effect of Insulin Degludec in Combination With Liraglutide and Metformin in Subjects With Type 2 Diabetes Qualifying for Treatment Intensification
Novo Nordisk A/S
NCT01664247
Comparison of Two Basal Insulins for Patients With Type 2 Diabetes Taking Oral Diabetes Medicines and Exenatide
Eli Lilly and Company
NCT00560417
Efficacy and Long-Term Safety of Vildagliptin as Monotherapy in Patients With Type 2 Diabetes
Novartis
NCT00821977
Dose-Ranging Study in Treatment Naive Type 2 Diabetes Mellitus(T2DM)
GlaxoSmithKline
NCT00500331
An Online System to Improve Diabetes Self-Care
Robert Wood Johnson Foundation
NCT00119938
OpT2mise Glucose Control in Type 2 Diabetes Mellitus (DM) With Insulin Pump Therapy
Medtronic Diabetes
NCT01182493
A Study of Taspoglutide Versus Placebo for the Treatment of Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin Plus Pioglitazone.
Hoffmann-La Roche
NCT00744367
Long-Term Effects of Insulin Plus Metformin Regimens on the Overall and Postprandial Glycemic Control of Patients With Type 2 Diabetes
Eli Lilly and Company
NCT00191464
Afrezza® INHALE-1 Study in Pediatrics
Mannkind Corporation
NCT04974528
Linagliptin and Metformin Versus Linagliptin in Newly Diagnosed, Untreated Type 2 Diabetes
Boehringer Ingelheim
NCT01512979
Dulce Digital-Me: An Adaptive mHealth Intervention for Underserved Hispanics With Diabetes
Scripps Whittier Diabetes Institute
NCT03130699
Efficacy and Safety of Semaglutide Once-weekly Versus Placebo as add-on to SGLT-2i in Subjects With Type 2 Diabetes Mellitus
Novo Nordisk A/S
NCT03086330
Improving Physical Activity Through a mHealth Intervention in Cardio-metabolic Risk Patients
Massachusetts General Hospital
NCT02551640
Understanding of Genetic Risk Information for Type 2 Diabetes
Duke University
NCT01186354
Comparison of Biphasic Insulin Aspart 70/30 Versus Insulin Glargine in Subjects With Type 2 Diabetes
Novo Nordisk A/S
NCT00097877
A Study of DPP-IV Inhibitor in Patients With Type 2 Diabetes
Hoffmann-La Roche
NCT00111670
Linagliptin Versus Placebo in Type 2 Diabetic Patients With Inadequate Glycaemic Control on Metformin in Combination With Pioglitazone
Boehringer Ingelheim
NCT00996658
Post Approval Study of the Eversense® Continuous Glucose Monitoring
Senseonics
NCT03908125
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 42 |
| Phase 2 | 38 |
| Phase 3 | 74 |
| Phase 4 | 26 |
Top Sponsors
Named interventions
Most-linked intervention names on Diabetes Mellitus, Type 2 records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Diabetes Mellitus, Type 2 trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Diabetes Mellitus, Type 2 page
351 registered trials, 63 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 63 Diabetes Mellitus, Type 2 trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- Novo Nordisk A/S sponsors the most Diabetes Mellitus, Type 2 trials on record, review their full trial history before evaluating a specific study. See Novo Nordisk A/S's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Diabetes Mellitus, Type 2 condition card totals 351 registered trials; most-linked intervention Placebo; top US site state California. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.